2908 completed, 344 terminated, 290 unknown, 202 recruiting. 4066 Phase 3, 523 Phase 2.
Follow Metabolic Diseases: new trials by email Literature Review of Metabolic Diseases trials Research Report on Metabolic Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Postpartum Semaglutide to Reduce Cardiometabolic Risk After Gestational Diabetes Mellitus Semaglutide (Wegovy) weekly injection - Gestational Diabetes Mellitus (GDM), Metabolic Syndrome | Phase 2 / Phase 3 | Not yet recruiting | University of Massachusetts, Worcester | 226 | 2027-09-01 | 2026-09-28 |
| CKM For Safe Use of SGLT2i in Type 1 Diabetes Sotagliflozin Low Dose, Sotagliflozin High Dose, Dual Continuous Glucose and Ketone Monitor - Type 1 Diabetes (T1D) | Phase 3 | Not yet recruiting | University of California, San Diego | 52 | 2027-04-01 | 2026-11-04 |
| A Study to Investigate the Safety, Pharmacokinetics (PK), and Efficacy of Garetosmab in Children and Adolescents With Fibrodysplasia Ossificans Progressiva (FOP) garetosmab - Fibrodysplasia Ossificans Progressiva, FOP | Phase 3 | Not yet recruiting | Regeneron Pharmaceuticals | 18 | 2027-02-02 | 2026-11-12 |
| A Study to Evaluate the Effectiveness and Safety of the Drug AZD6234 for Managing Weight in Adults Who Are Obese or Overweight. These Participants May or May Not Also Have Type 2 Diabetes AZD6234, Placebo - Obesity, Overweight | Phase 3 | Not yet recruiting | AstraZeneca | 330 | 2027-01-04 | 2026-11-06 |
| A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of NXC-201 Compared With Daratumumab With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) in Newly Diagnosed Systemic AL Amyloidosis NXC-201, Dara-CyBorD - Light Chain (AL) Amyloidosis | Phase 3 | Not yet recruiting | Nexcella Inc. | 260 | 2027-01-01 | 2026-07-16 |
| Verapamil In Preclinical Type 1 Diabetes Verapamil 120 Mg/24 Hours Oral Capsule, Extended Release, Placebo, blood sampling - Type 1 Diabetes | Phase 2 / Phase 3 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 50 | 2027-01-01 | 2026-10-22 |
| Diabetes Prevention Through Genetics, Familial History and Behavior Change LEGACY DPP, DPP - Prediabetes, Weight Loss | Phase 2 / Phase 3 | Not yet recruiting | Morehouse School of Medicine | 400 | 2027-01-01 | 2026-10-20 |
| A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin, and Placebo on LDL-C in LLT-naïve Patients Laroprovstat, Rosuvastatin 1, Rosuvastatin 2 - Hypercholesterolemia | Phase 3 | Not yet recruiting | AstraZeneca | 204 | 2026-12-21 | 2026-11-12 |
| Linvoseltamab Versus Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone (Dara-Vcd) in Adult Participants With Newly Diagnosed Systemic Light Chain Amyloidosis Linvoseltamab, Daratumumab, Bortezomib - Newly Diagnosed Amyloidosis, Amyloidosis Stage I-IIIA | Phase 3 | Not yet recruiting | Regeneron Pharmaceuticals | 382 | 2026-12-18 | 2026-10-28 |
| The Efficacy and Safety of Venglustat Compared With Cerezyme in Pediatric Participants 2 to 11 Years of Age With Gaucher Disease Type 3 (GD3) Venglustat, Imiglucerase - Gaucher's Disease Type III | Phase 3 | Not yet recruiting | Sanofi | 18 | 2026-12-11 | 2026-11-10 |
| Long-Term Safety and Tolerability of Nizubaglustat in Participants With Rare Lysosomal Disorders AZ-3102 - Niemann-Pick Disease Type C, GM2 Gangliosidosis | Phase 2 / Phase 3 | Not yet recruiting | Azafaros B.V. | 218 | 2026-12-10 | 2026-10-21 |
| Efficacy and Safety of Modafinil to Treat Fatigue in People With Mitochondrial Disease. Modafinil (M), Placebo - Mitochondrial Disease | Phase 3 | Not yet recruiting | Kenneth Myers, MD | 15 | 2026-12-01 | 2026-10-26 |
| Efficacy and Safety of Semaglutide Versus Placebo on Cardiometabolic Profile in Patients With Schizophrenia With Metabolic Syndrome Semaglutide + TAU, Placebo + TAU - Schizophrenia Disorder, Metabolic Syndrome | Phase 3 | Not yet recruiting | All India Institute of Medical Sciences, Bhubaneswar | 600 | 2026-12-01 | 2026-08-18 |
| A Study to Test the Non-Inferiority of Ferric Bepectate IV Against Ferric Carboxymaltose in Patients With Iron Deficiency Anemia Ferric Bepectate IV Injection, Ferric Carboxymaltose Injection [Ferinject], Ferric Carboxymaltose Injection [Injectafer®] - Iron Deficiency Anemia (IDA) | Phase 3 | Not yet recruiting | AFT Pharmaceuticals, Ltd. | 1366 | 2026-12-01 | 2026-08-20 |
| Intracerebroventricular Tralesinidase Alfa in Participants With MPS IIIB (Sanfilippo Syndrome Type B) Tralesinidase alfa (TA) - MPS IIIB | Phase 3 | Not yet recruiting | Spruce Biosciences | 14 | 2026-12-01 | 2026-09-21 |
| Effects of Ketones on Brain Energetics and Alcohol Consumption in Alcohol Use Disorder Kenetik, magnetic resonance imaging scan, Alcohol bar lab - Alcohol Use Disorder, Ketosis | Phase 2 / Phase 3 | Recruiting | University of Pennsylvania | 60 | 2026-12-01 | 2026-10-21 |
| A Clinical Study to Evaluate the Effects of Enicepatide Versus Tirzepatide in Participants With Type 2 Diabetes and Inadequate Blood Sugar Control on Oral Glucose-Lowering Medications Enicepatide, Tirzepatide - Type 2 Diabetes Mellitus | Phase 3 | Not yet recruiting | Hoffmann-La Roche | 948 | 2026-12-01 | 2026-10-22 |
| A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased Cardiovascular Risk Eloralintide, Placebo - Obesity, Overweight | Phase 3 | Not yet recruiting | Eli Lilly and Company | 3000 | 2026-12-01 | 2026-11-03 |
| A Study to Learn How Well Lucerastat Works and How Safe it is in Untreated Adult Male Participants With Fabry Disease Lucerastat - Fabry Disease | Phase 3 | Recruiting | Idorsia Pharmaceuticals Ltd. | 16 | 2026-12-01 | 2026-11-03 |
| Alpha-Lipoic Acid Added to Dapagliflozin and Insulin Resistance in Type 2 Diabetes Alpha-Lipoic Acid (ALA), Placebo - Diabetes Mellitus, Type 2, Insulin Resistance Syndrome | Phase 3 | Not yet recruiting | Fayoum University | 70 | 2026-12-01 | 2026-11-12 |
Showing 20 of 4066. Sign in to see all of them.
Diabetes Mellitus, Type 2 (1435) · Diabetes Mellitus (782) · Diabetes Mellitus, Type 1 (317) · Hypercholesterolemia (275) · Dyslipidemias (202) · Osteoporosis (194) · Insulin Resistance (178) · Hyperlipidemias (165) · Obesity (161) · Hypertension (118) · Metabolic Syndrome (106) · Anemia, Iron-Deficiency (92) · Renal Insufficiency, Chronic (92) · Amyotrophic Lateral Sclerosis (90) · Cardiovascular Diseases (89)
Nutritional and Metabolic Diseases (4061) · Glucose Metabolism Disorders (2255) · Endocrine System Diseases (2180) · Diabetes Mellitus (1339) · Lipid Metabolism Disorders (728) · Pathological Conditions, Signs and Symptoms (603) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (565) · Genetic Diseases, Inborn (528) · Nervous System Diseases (473) · Metabolism, Inborn Errors (434) · Dyslipidemias (430) · Immune System Diseases (415) · Cardiovascular Diseases (373) · Vascular Diseases (369)
Metformin (322) · Insulin Glargine (193) · Sitagliptin Phosphate (133) · Atorvastatin (119) · Ezetimibe (100) · Insulin Aspart (92) · semaglutide (91) · dapagliflozin (89) · Rosuvastatin Calcium (85) · Pioglitazone (83) · glimepiride (82) · Simvastatin (76) · Vildagliptin (76) · Insulin (74) · Liraglutide (71)
Novo Nordisk A/S (234) · AstraZeneca (186) · Sanofi (145) · Eli Lilly and Company (144) · Merck Sharp & Dohme LLC (124) · Takeda (89) · Organon and Co (81) · Novartis Pharmaceuticals (80) · Amgen (71) · Pfizer (55) · Boehringer Ingelheim (53) · Novartis (51) · GlaxoSmithKline (39) · Hoffmann-La Roche (33) · Tanabe Pharma Corporation (24)
United States (1763) · Canada (755) · Germany (701) · United Kingdom (577) · Spain (565) · France (543) · Italy (509) · Poland (481) · Mexico (411) · Australia (409) · Japan (392) · China (388) · Netherlands (375) · Brazil (348) · South Korea (348)
PMID 38770818, PMID 39963952, PMID 40576086, PMID 22236356, PMID 31903692, PMID 32998732, PMID 35044568, PMID 22913891, PMID 33078867, PMID 38682786, PMID 23010561, PMID 25504028, PMID 21518985, PMID 32267058, PMID 38979716, PMID 26580237, PMID 26894924, PMID 27402391, PMID 27777279, PMID 30183102, PMID 34298554, PMID 35472672, PMID 24517339, PMID 31606880, PMID 32306296, PMID 21450987, PMID 21883806, PMID 22193143, PMID 22234149, PMID 22862847, PMID 23130654, PMID 23186975, PMID 24170235, PMID 24786834, PMID 26232910, PMID 27977934, PMID 30615985, PMID 30880443, PMID 31769496, PMID 31797522, PMID 32324065, PMID 32324082, PMID 32372382, PMID 32501595, PMID 32648108, PMID 33874971, PMID 36542287, PMID 17878242, PMID 18093207, PMID 19245711
2015 (46), 2008 (45), 2009 (40), 2025 (37), 2014 (35), 2023 (35), 2016 (33), 2018 (32), 2005 (30), 2017 (30), 2019 (22), 2004 (7), P30CA015083 (2), R21AA031088 (2), U01DK048489 (2)